{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T01:57:16Z","timestamp":1783216636429,"version":"3.54.6"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bbrep.2020.100832","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T14:03:10Z","timestamp":1602770590000},"page":"100832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cucurbitacin E and I target the JAK\/STAT pathway and induce apoptosis in S\u00e9zary cells"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-5700","authenticated-orcid":false,"given":"Isabella J.","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoba J.","family":"Out-Luiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5325-1888","authenticated-orcid":false,"given":"Cornelis P.","family":"Tensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2020.100832_bib1","series-title":"Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors. 2012","author":"Rodd","year":"2012"},{"issue":"2","key":"10.1016\/j.bbrep.2020.100832_bib2","first-page":"89","article-title":"Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants","volume":"2","author":"RLJJotAAoD","year":"1980"},{"issue":"4","key":"10.1016\/j.bbrep.2020.100832_bib3","first-page":"397","article-title":"Clinicopathological spectrum of mycosis fungoides","volume":"18","author":"Kazakov","year":"2004"},{"issue":"19","key":"10.1016\/j.bbrep.2020.100832_bib4","first-page":"1978","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004"},{"issue":"6","key":"10.1016\/j.bbrep.2020.100832_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamadermatol.2017.0361","article-title":"Cutaneous T-cell LymphomasCutaneous T-cell LymphomasJAMA Dermatology patient page","volume":"153","author":"Dai","year":"2017","journal-title":"JAMA Dermatology"},{"issue":"Suppl 3","key":"10.1016\/j.bbrep.2020.100832_bib6","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1080\/10428190310001623766","article-title":"Cutaneous T-cell lymphoma: epidemiology, etiology, and classification","volume":"44","author":"Willemze","year":"2003","journal-title":"Leuk. Lymphoma"},{"issue":"21","key":"10.1016\/j.bbrep.2020.100832_bib7","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbrep.2020.100832_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/CCO.0000000000000161","article-title":"Recent advances in primary cutaneous T-cell lymphoma","volume":"27","author":"DeSimone","year":"2015","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.bbrep.2020.100832_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/annonc\/mdy207","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"30","author":"Quaglino","year":"2019","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"issue":"6","key":"10.1016\/j.bbrep.2020.100832_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"32","key":"10.1016\/j.bbrep.2020.100832_bib11","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.bbrep.2020.100832_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch. Dermatol."},{"issue":"31","key":"10.1016\/j.bbrep.2020.100832_bib13","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"23","key":"10.1016\/j.bbrep.2020.100832_bib14","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1002\/cncr.27627","article-title":"Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas","volume":"118","author":"Quaglino","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbrep.2020.100832_bib15","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8829.1","article-title":"An overview of cutaneous T cell lymphomas","volume":"5","author":"Bagherani","year":"2016","journal-title":"F1000Research."},{"issue":"3","key":"10.1016\/j.bbrep.2020.100832_bib16","first-page":"256","article-title":"Sezary syndrome: old enigmas, new targets","volume":"14","author":"Nicolay","year":"2016","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG"},{"issue":"3","key":"10.1016\/j.bbrep.2020.100832_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1203475419840629","article-title":"Existing and emerging therapies for cutaneous T-cell lymphoma","volume":"23","author":"Van-de-Velde","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"issue":"9","key":"10.1016\/j.bbrep.2020.100832_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.bbrep.2020.100832_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French society of bone marrow transplantation and French study group on cutaneous lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"29","key":"10.1016\/j.bbrep.2020.100832_bib20","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.bbrep.2020.100832_bib21","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/0008-5472.CAN-07-6398","article-title":"Novel and highly recurrent chromosomal alterations in Sezary syndrome","volume":"68","author":"Vermeer","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrep.2020.100832_bib22","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.bbrep.2020.100832_bib23","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2020.100832_bib24","article-title":"The polymorphisms of IL-6\/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility","author":"Olszewska","year":"2020","journal-title":"Arch. Dermatol. Res."},{"issue":"12","key":"10.1016\/j.bbrep.2020.100832_bib25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/gcc.22679","article-title":"Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides","volume":"57","author":"Bastidas Torres","year":"2018","journal-title":"Gene Chromosome Canc."},{"issue":"4","key":"10.1016\/j.bbrep.2020.100832_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2020.100832_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbrep.2020.100832_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2017.02.019","article-title":"JAK\/STAT pathway directed therapy of T-cell leukemia\/lymphoma: inspired by functional and structural genomics","volume":"451","author":"Waldmann","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"issue":"11","key":"10.1016\/j.bbrep.2020.100832_bib29","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"Perez","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bbrep.2020.100832_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.leu.2402093","article-title":"Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells","volume":"15","author":"Eriksen","year":"2001","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bbrep.2020.100832_bib31","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2008.138","article-title":"Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells","volume":"128","author":"Zhang","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.bbrep.2020.100832_bib32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.jid.5701246","article-title":"Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells","volume":"128","author":"van Kester","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"20","key":"10.1016\/j.bbrep.2020.100832_bib33","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/sj.onc.1208470","article-title":"Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity","volume":"24","author":"Sun","year":"2005","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bbrep.2020.100832_bib34","first-page":"1270","article-title":"Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase\/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice","volume":"63","author":"Blaskovich","year":"2003","journal-title":"Canc. Res."},{"issue":"17","key":"10.1016\/j.bbrep.2020.100832_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0973-7847.156314","article-title":"Cucurbitacins - an insight into medicinal leads from nature","volume":"9","author":"Kaushik","year":"2015","journal-title":"Phcog. Rev."},{"issue":"3","key":"10.1016\/j.bbrep.2020.100832_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1039\/b418841c","article-title":"Cucurbitacins and cucurbitane glycosides: structures and biological activities","volume":"22","author":"Chen","year":"2005","journal-title":"Nat. Prod. Rep."},{"issue":"1","key":"10.1016\/j.bbrep.2020.100832_bib37","first-page":"77","article-title":"Cucurbitacins - a promising target for cancer therapy","volume":"7","author":"Alghasham","year":"2013","journal-title":"Int. J. Health Sci."},{"issue":"5","key":"10.1016\/j.bbrep.2020.100832_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00431220","article-title":"A continuous T-cell line from a patient with Sezary syndrome","volume":"279","author":"Kaltoft","year":"1987","journal-title":"Arch. Dermatol. Res."},{"issue":"5","key":"10.1016\/j.bbrep.2020.100832_bib39","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1084\/jem.154.5.1403","article-title":"Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor","volume":"154","author":"Gootenberg","year":"1981","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bbrep.2020.100832_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"6","key":"10.1016\/j.bbrep.2020.100832_bib41","first-page":"394","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"Idrugs : the investigational drugs journal"},{"issue":"7","key":"10.1016\/j.bbrep.2020.100832_bib42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2013-0198","article-title":"AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors","volume":"18","author":"Plimack","year":"2013","journal-title":"Oncol."},{"issue":"6","key":"10.1016\/j.bbrep.2020.100832_bib43","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat","year":"2009","journal-title":"Canc. Cell"},{"issue":"1","key":"10.1016\/j.bbrep.2020.100832_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbrep.2020.100832_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178910","article-title":"Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway","volume":"12","author":"Murtaza","year":"2017","journal-title":"PloS One"},{"issue":"14","key":"10.1016\/j.bbrep.2020.100832_bib46","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1158\/0008-5472.CAN-09-0536","article-title":"Cucurbitacin B induces apoptosis by inhibition of the JAK\/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells","volume":"69","author":"Thoennissen","year":"2009","journal-title":"Canc. Res."},{"issue":"4","key":"10.1016\/j.bbrep.2020.100832_bib47","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3892\/or.2015.3749","article-title":"Cucurbitacin I inhibits cell migration and invasion and enhances chemosensitivity in colon cancer","volume":"33","author":"Song","year":"2015","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.bbrep.2020.100832_bib48","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4161\/cbt.7.8.6263","article-title":"JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)\/M cell cycle arrest and apoptosis augment","volume":"7","author":"Su","year":"2008","journal-title":"Canc. Biol. Ther."},{"key":"10.1016\/j.bbrep.2020.100832_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2014.05.005","article-title":"Cucurbitacin-I, a natural cell-permeable triterpenoid isolated from Cucurbitaceae, exerts potent anticancer effect in colon cancer","volume":"219","author":"Kim","year":"2014","journal-title":"Chem. Biol. Interact."},{"issue":"23","key":"10.1016\/j.bbrep.2020.100832_bib50","first-page":"5843","article-title":"Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation","volume":"10","author":"Si","year":"2019","journal-title":"J. Canc."},{"issue":"9","key":"10.1016\/j.bbrep.2020.100832_bib51","first-page":"1799","article-title":"Growth inhibitory effect of Cucurbitacin E on breast cancer cells","volume":"6","author":"Lan","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"2\u20133","key":"10.1016\/j.bbrep.2020.100832_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.toxlet.2012.11.014","article-title":"The cucurbitacins E, D and I: investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver","volume":"216","author":"Abbas","year":"2013","journal-title":"Toxicol. Lett. (Amst.)"},{"issue":"5","key":"10.1016\/j.bbrep.2020.100832_bib53","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/jid.2012.10","article-title":"MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53","volume":"132","author":"Manfe","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.bbrep.2020.100832_bib54","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.jid.2016.05.126","article-title":"Inactivation of RUNX3\/p46 promotes cutaneous T-cell lymphoma","volume":"136","author":"Haider","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.bbrep.2020.100832_bib55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/10428194.2014.929673","article-title":"Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage","volume":"56","author":"Savorani","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.bbrep.2020.100832_bib56","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bbrep.2020.100832_bib57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-016-0410-8","article-title":"Genetics of cutaneous T cell lymphoma: from bench to bedside","volume":"17","author":"Damsky","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"issue":"7","key":"10.1016\/j.bbrep.2020.100832_bib58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jid.2016.04.027","article-title":"Sezary syndrome: translating Genetic diversity into personalized medicine","volume":"136","author":"Chevret","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.bbrep.2020.100832_bib59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1431927602010346","article-title":"The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs","volume":"8","author":"Watanabe","year":"2002","journal-title":"Microsc. Microanal. : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada"},{"issue":"8","key":"10.1016\/j.bbrep.2020.100832_bib60","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.4049\/jimmunol.177.8.5032","article-title":"A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor","volume":"177","author":"Nagy","year":"2006","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.bbrep.2020.100832_bib61","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: a small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbrep.2020.100832_bib62","first-page":"1","article-title":"Protocols for screening chemical agents and natural products against animal tumors and other biological systems","volume":"25","author":"Cancer Chemotherapy National Service Center","year":"1962","journal-title":"Cancer Chemother. Rep."},{"issue":"1\u20132","key":"10.1016\/j.bbrep.2020.100832_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijpharm.2007.10.015","article-title":"Screening of biochemical modulator by tumor cell permeability of doxorubicin","volume":"354","author":"Sadzuka","year":"2008","journal-title":"Int. J. Pharm."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580820301424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580820301424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:45:58Z","timestamp":1762501558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580820301424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":63,"alternative-id":["S2405580820301424"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2020.100832","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cucurbitacin E and I target the JAK\/STAT pathway and induce apoptosis in S\u00e9zary cells","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2020.100832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100832"}}